|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Selection of patients with hepatocellular carcinoma for livertransplantation:Past and future显示文摘The aim of liver transplantation(LT) for hepatocellular carcinoma(HCC) is to ensure a rate of disease-free survival similar to that of patients transplanted due to benign disease. Therefore, we are forced to adopt strict criteria when selecting candidates for LT and prioritizing patients on the waiting list(WL), to have clarified indications for bridging therapy for groups at risk for progression or recurrence, and to establish certain limits for downstaging therapies. Although the Milan criteria(MC) remain the standard and most employed criteria for indication of HCC patients for LT by far, in the coming years, criteria will be consolidated that take into account not only data regarding the size/volume and number of tumors but also their biology. This criteria will mainly include the alpha fetoprotein(AFP) values and, in view of their wide variability, any of the published logarithmic models for the selection of candidates for LT. Bridging therapy is necessary for HCC patients on the WL who meet the MC and have the possibility of experiencing a delay for LT greater than 6 mo or any of the known risk factors for recurrence. It is difficult to define single AFP values that would indicate bridging therapy(200, 300 or 400 ng/m L); therefore, it is preferable to rely on the criteria of a French AFP model score > 2. Other single indications for bridging therapy include a tumor diameter greater than 3 cm, more than one tumor, and having an AFP slope greater than 15 ng/m L per month or > 50 ng/m L for three months during strict monitoring while on the WL. When considering the inclusion of patients on the WL who do not meet the MC, it is mandatory to determine their eligibility for downstaging therapy prior to inclusion. The upper limit for this therapy could be one lesion up to 8 cm, 2-3 lesions with a total tumor diameter up to 8 cm, or a total tumor volume of 115 cm^3. Lastly, liver allocation and the prioritization of patients with HCC onthe WL should take into account the recently described HCC model for end-stage liver disease, which considers hepatic function, HCC size and the number and the log of AFP values. This formula has been calibrated with the survival data of non-HCC patients and produces a dynamic and more accurate assessment model. | Arturo Soriano Aranzazu Varona Rajesh Gianchandani Modesto Enrique Moneva Javier Arranz Antonio Gonzalez Manuel Barrera | 2016 | World Journal of Hepatology2016，8，1： | 6 |
| 2 | Synthesis and properties of fluorescent 1,8-naphthalimide dyes for application in liquid crystal displays显示文摘 | Grabchev I Moneva I Bojinov V | 2000 | J Mater Chem2000，10，： | 1 |
| 3 | Environmental Dis- closures and Compulsory Accounting Standards: the Case of Spanish Annum Reports 显示文摘 | LLENA F JOSE M MONEVA BLANCA H | 2007 | Business Strategy and the Environment2007，，16： | 1 |
| 4 | Synthesis and properties of vinilic copolymers with fluorescent moieties as optical brighteners for liquid crystals显示文摘 | Moneva I | 1999 | Appl Polym Sci1999，74，： | 1 |
| 5 | Polymerization of styrene in the presence of some triazine stilbene fluorescent brighteners显示文摘 | Grabchev I Moneva I | 1998 | Die Angewandte M olekulare Chemie1998，263，1： | 1 |
| 6 | 显示文摘 | Grabchev I Moneva I | 1999 | Journal of Applied Polymer Science1999，74，1： | 1 |
| 7 | Environmental Reporting in the Spanish Wind Energy Sec- tor: An Institutional View 显示文摘 | Mosene Jose A Burritt Roger L Sanagusttn M V Moneva Jose M Tingey-Holyoak Joanne | 2013 | Journal of Cleaner Production2013，，40： | 1 |
| 8 | 显示文摘 | Grabchev I Moneva I | 1998 | Die Angewandte Makromolekulare Chemie1998，263，1： | 1 |
| 9 | : The Corporate Stakeholder Commitment and Social and Financial Performance 显示文摘 | Moneva J M | 2007 | Industrial Manage- ment2007，，3： | 1 |
| 10 | Environmental Disclosures in Annual Reports of Large Companies in Spain 显示文摘 | Moneva J M F Llena | 2000 | European Accounting Review2000，9，1： | 1 |
| 11 | The Corporate Stakeholder Commit-ment and Social and Financial Performance显示文摘 | Moneva J.M | | 0，，01： | 1 |
| 12 | Corporate social reporting and reputation risk management显示文摘 | Jan Bebbington Carlos Larrinaga Jose M Moneva | 2008 | Account- ing Auditing & Accountability Journal2008，，21： | 1 |
| 13 | Synthesis and properties of vinylic copolymers with fluorescent moieties as optical brightenem for liquid crystals显示文摘 | I Grabchev I Moneva | 1999 | Journal of Applied Polymer Science1999，74，： | 1 |
| 14 | 查看详情显示文摘 | I Grabchev I Moneva V Bojinov | | 0，，： | 1 |
| 15 | Corporate environmental and financial performance: a multivariate approach显示文摘 | José M. Moneva Eduardo Ortas | 2010 | Industrial Management & Data Systems2010，，2： | 1 |
| 16 | Rare origin of a retroperitoneal mass:Castleman's disease显示文摘 | GARCIA MIRALLES GRAVALOS R BENEJAM GUAL J MONEVA P E | 1998 | Actas Urol Esp1998，22，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员